ClinicalTrials.gg
RecruitingNCT07016074Updated Nov 2, 2026

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

A Phase 2 interventional study of Sodium Nitrate and Placebo in Kidney Injury, Acute, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Michigan · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
93rd of 237
100 · median 67
Started
2025
with 21 others
Phase 2
54 of 370
11 open now
Primary completion
2026-11
later than 19 of 87 live
Registered
341st of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 93rd largest by planned enrollment of the 237 interventional ones that give a count, is one of 22 that started in 2025, is one of 54 in phase 2, reaches primary completion later than 19 of the 87 other live ones, and was the 341st registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.

Read the detailed description

The timing of the follow-up blood test was changed from 48 hours (± 12 hours) to 72 hours (± 36 hours) after contrast exposure. This change allows participants more flexibility to complete their lab work at a convenient outpatient location without requiring a return visit within a narrow time window. The new timing still falls within the period when kidney function changes from contrast exposure would be expected to appear, so the study's ability to detect these changes is preserved and safety monitoring remains consistent.

03

Conditions studied

  • Kidney Injury, Acute

Browse trials for

Keywords

  • Sodium Nitrate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned coronary angiogram or contrast-enhanced CT scan.
  • High-risk for contrast-associated acute kidney injury (AKI) with creatine/ (GFR) within 90 days as defined as:

    1. Undergoing coronary angiogram with GFR \<45 mL/min/1.73m2 OR
    2. Undergoing coronary angiogram with GFR \<60 mL/min/1.73m2 and concurrent risk of AKI as defined by Hamilton et al. BMC2 risk prediction model ≥ 7%.

      OR

    3. Undergoing contrast-enhanced CT scan with GFR\<45 mL/min/1.73m2
  • If subject is a woman of , subject agrees to the use of highly effective starting at screening and during study participation.
  • Ability to take oral medication and be willing to adhere to the study intervention regimen.
  • Ability to understand and willingness to agree to an

Exclusion criteria

Exclusion Criteria:

  • Already fulfilling definition of acute kidney injury prior to contrast exposure by kidney disease improving global outcomes (KDIGO) criteria (absolute increase in creatinine from baseline of 0.3mg/dL or more OR relative increase in creatine of 50% or more from baseline).
  • Primary indication for Percutaneous Coronary Intervention (PCI) including acute ST-segment elevation myocardial infarction
  • End-stage renal disease actively on dialysis.
  • Received any intravenous or intraarterial contrast within five days from planned contrast administration.
  • Cardiac arrest within 14 days of planned contrast administration.
  • Systolic blood pressure \< 100mmHg or diastolic blood pressure \<60mmHg OR currently receiving inotropes or vasopressors for hemodynamic support.
  • History of or known allergy to any of the components of the product or placebo including sodium nitrate, inorganic nitrate, beet root juice, or lactose. This does not include lactose intolerance.
  • Pregnancy or nursing female
  • Participation in other investigational trials within the past 30 days prior to enrollment.
  • Use of tadalafil within 48 hours, sildenafil or vardenafil within 24 hours, and avanafil within 12 hours of initiation of trial medication. If participant is on continuous dosing of tadalafil, sildenafil, vardenafil, or avanafil, they will be excluded from the trial. If participant is on intermittent dosing of tadalafil, sildenafil, vardenafil, or avanafil, patient agrees to withhold use of medication for duration of medication treatment extending 48 hours after the final dose.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Dispensing, and Labeling: The University of Michigan Research Pharmacy will compound sodium nitrate and placebo capsules. Placebo capsules will be compounded by filling a matching capsule with lactose.

    Drug: Placebo

  • Experimental
    Sodium Nitrate

    Dispensing, and Labeling: The University of Michigan Research Pharmacy will compound sodium nitrate and placebo capsules. Sodium nitrate powder will be measure and used for the active capsules with adding lactose as a filler.

    Drug: Sodium Nitrate

Interventions

  • The study drug is sodium nitrate capsule at a dose of 12mmol of nitrate. This medication will be given orally 1-8 hours before the planned contrast administration and then once per day for a total of four doses.

    Also known as: Chili saltpeter

  • DrugPlacebo

    The placebo control medication will be a capsule filled with lactose that will be taken in the same manner and schedule as the sodium nitrate capsule

06

What researchers measure

Primary outcomes

  1. Percent of participants receiving the first dose of blinded study drug within 1-8 hours prior to contrast exposure

    Success is defined as greater than 80% of patients receiving the first dose of blind study drug within 1-8 hours prior to contrast exposure.

    Time frame: Approximately 34 days

  2. Percent of participants completing full course of 4 doses of blinded study drug

    Success is defined as greater than 80% of patients completing the full course of 4 doses of blinded study drug

    Time frame: Approximately 34 days

  3. Percent of participants with 48-hour basic metabolic panel collected between 36-108 hours of contrast exposure

    Success is defined as greater than 80% of patients having appropriately collected 48-hour basic metabolic panel collected 36-108 hours of contrast exposure

    Time frame: Approximately 34 days

  4. Percent of participants who had completion of clinical outcome monitoring at 30-day follow-up interview

    Success is defined as greater than 80% of patients completing full clinical outcome monitoring at 30-day follow-up interview.

    Time frame: Approximately 34 days

  5. Percent of participants recruited to the trial for undergoing coronary angiogram

    Success is defined as four or more patients being recruited into the study prior to coronary angiogram each month of the study averaged over the study period

    Time frame: Approximately 34 days

  6. Percent of participants recruited to the trial for undergoing a contrast-enhanced CT scan

    Success is defined as four or more patients being recruited into the study prior to contrast-enhanced CT scan each month of the study averaged over the study period.

    Time frame: Approximately 34 days

Secondary outcomes

  1. Number of participants who develop of Contrast-Associated Acute Kidney Injury (CA-AKI)

    As defined by creatinine measurement at 48 hours after contrast administration meeting Kidney Disease Improving Global Outcomes (KDIGO) criteria

    Time frame: Approximately 34 days

  2. Number of participants who had initiation of renal replacement therapy within 30 days of planned contrast administration for patients that did not have active need for dialysis prior to study enrollment

    Time frame: Approximately 34 days

  3. Number of participants with all-cause mortality within 30 days of planned contrast administration as defined by cessation of life due to any cause

    Time frame: Approximately 34 days

  4. Number of participants with major adverse cardiovascular events (MACE)

    MACE is a composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke within 30 days of planned contrast administration

    Time frame: Approximately 34 days

  5. Number of participants with cardiovascular death within 30 days of planned contrast administration as defined by cessation of life deemed secondary to cardiovascular cause

    Time frame: Approximately 34 days

  6. Number of participants with non-fatal myocardial infarction within 30 days of planned contrast administration

    Time frame: Approximately 34 days

  7. Number of participants with non-fatal stroke within 30 days of planned contrast administration

    Time frame: Approximately 34 days

  8. Number of participants with major adverse kidney events (MAKE)

    MAKE is a composite outcome of death, new renal replacement therapy, or persistent renal dysfunction within 30 days of planned contrast administration. Persistent renal dysfunction is defined as creatinine value greater than or equal to 200% of baseline value at 30 days

    Time frame: Approximately 34 days

  9. Number of participants with persistent renal dysfunction at 30 days of planned contrast administration

    Renal dysfunction is defined as creatinine value greater than or equal to 200% of baseline value at 30 days.

    Time frame: Approximately 34 days

  10. Number of participants with new onset hypotension

    Time frame: Approximately 34 days

  11. Number of adverse events within 30 days of planned contrast administration

    Time frame: Approximately 34 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

Of 39 non-industry phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 17 months is below that.

Counting every sponsor, half of 57 studies reached it within 29 months; a quarter within 16 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Oct 2026 → Nov 2026 and completion Nov 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 11, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Nov 30, 2026was Oct 2026
CompletionEst.
Dec 30, 2026was Nov 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Nov 30, 2026
Nov 2, 2026
Study completion
Nov 2026→Dec 30, 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Oct 2026→Nov 30, 2026
    Study completion Nov 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07016074
Responsible party
Hitinder Gurm (Professor of Cardiovascular Medicine, Professor of Internal Medicine, and Chief Medical Officer, Medical School, University of Michigan) — Principal investigator
First posted
Jun 11, 2025
Start date
Jun 30, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Allison Schley
Contact
schleya@umich.edu
734-232-9051
Hitinder Gurm, MBBS
study chair · University of Michigan
David Hamilton, MD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium nitrate

Start the discussion